Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2016 (2016), Article ID 4705492, 4 pages
http://dx.doi.org/10.1155/2016/4705492
Case Report

Severe Rhabdomyolysis as Complication of Interaction between Atorvastatin and Fusidic Acid in a Patient in Lifelong Antibiotic Prophylaxis: A Dangerous Combination

1Medical Department, Infectious Diseases Division, National Hospital Faroe Islands, Tórshavn, Faroe Islands
2Infectious Diseases Research Unit, Odense University Hospital and University of Southern Denmark, Odense, Denmark
3Faculty of Science and Technology, University of the Faroe Islands, Tórshavn, Faroe Islands

Received 28 September 2016; Revised 13 November 2016; Accepted 4 December 2016

Academic Editor: Mamede de Carvalho

Copyright © 2016 Anirban Nandy and Shahin Gaïni. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. J. Graham, J. A. Staffa, D. Shatin et al., “Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs,” The Journal of the American Medical Association, vol. 292, no. 21, pp. 2585–2590, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. M. A. Omar, J. P. Wilson, and T. S. Cox, “Rhabdomyolysis and HMG-CoA reductase inhibitors,” Annals of Pharmacotherapy, vol. 35, no. 9, pp. 1096–1107, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. C. M. Ballantyne, A. Corsini, M. H. Davidson et al., “Risk for myopathy with statin therapy in high-risk patients,” Archives of Internal Medicine, vol. 163, no. 5, pp. 553–564, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. P. D. Thompson, P. Clarkson, and R. H. Karas, “Statin-associated myopathy,” JAMA, vol. 289, no. 13, pp. 1681–1690, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. A. J. Burtenshaw, G. Sellors, and R. Downing, “Presumed interaction of fusidic acid with simvastatin,” Anaesthesia, vol. 63, pp. 656–658, 2008. View at Google Scholar
  6. C. Magee, S. A. Medani, S. F. Leavey, P. J. Conlon, and M. R. Clarkson, “Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin,” American Journal of Kidney Diseases, vol. 56, pp. e11–e15, 2010. View at Google Scholar
  7. D. H. Schreiber and T. R. Anderson, “Statin-induced rhabdomyolysis,” Journal of Emergency Medicine, vol. 31, no. 2, pp. 177–180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. R. H. Knopp, “Drug treatment of lipid disorders,” The New England Journal of Medicine, vol. 341, no. 7, pp. 498–511, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Wenisch, R. Krause, P. Fladerer, I. El Menjawi, and E. Pohanka, “Acute rhabdomyolysis after atorvastatin and fusidic acid therapy,” American Journal of Medicine, vol. 109, article no. 78, 2000. View at Google Scholar · View at Scopus
  10. A. Gupta, J. J. Harris, J. Lin, J. P. Bulgarelli, B. K. Birmingham, and S. W. Grimm, “Fusidic acid inhibits hepatic transporters and metabolic enzymes: potential cause of clinical drug-drug interaction observed with statin coadministration,” Antimicrobial Agents and Chemotherapy, vol. 60, no. 12, pp. 5986–5994, 2016. View at Publisher · View at Google Scholar
  11. P. H. Chong, J. D. Seeger, and C. Franklin, “Clinically relevant differences between the statins: implications for therapeutic selection,” American Journal of Medicine, vol. 111, no. 5, pp. 390–400, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. V. Fuhrmans, “Bayer discloses higher death toll from Baycol,” Wall Street Journal, vol. A10, 2002. View at Google Scholar
  13. J. Martin and H. Krum, “Cytochrome p450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant?” Drug Safety, vol. 26, no. 1, pp. 13–21, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. J. P. Deslypere and A. Vermeulen, “Rhabdomyolysis and simvastatin,” Annals of Internal Medicine, vol. 114, no. 4, p. 342, 1991. View at Google Scholar · View at Scopus
  15. R. J. Herman, “Drug interactions and the statins,” CMAJ, vol. 161, no. 10, pp. 1281–1286, 1999. View at Google Scholar · View at Scopus
  16. D. Williams and J. Feely, “Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors,” Clinical Pharmacokinetics, vol. 41, no. 5, pp. 343–370, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. L. J. Bontempo, “Rhabdomyolysis,” in Rosen's Emergency Medicine, J. Marx and R. Walls, Eds., pp. 1762–1769, Mosby, New York, NY, USA, 5th edition, 2002. View at Google Scholar
  18. R. Vanholder, M. S. Sever, E. Erek, and N. Lameire, “Rhabdomyolysis,” Journal of the American Society of Nephrology, vol. 11, no. 8, pp. 1553–1561, 2000. View at Google Scholar · View at Scopus
  19. C. E. Haas, Y. Magram, A. Mishra, L. González, and J.-M. Kaiser, “Rhabdomyolysis and acute renal failure following an ethanol and diphenhydramine overdose,” Annals of Pharmacotherapy, vol. 37, no. 4, pp. 538–542, 2003. View at Publisher · View at Google Scholar · View at Scopus